Hormone Resistant Prostate CancerThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

• By Date
• Specialty Filter
• Discussions
• Top 20

Pages: 1  2  

Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies Of Apoptone (HE3235) At AACR Molecular Targets ConferenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH), reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 17, 2009 Category: Consumer Health News Tags: prostate / prostate Cancer Source Type: news

Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies Of Apoptone (HE3235) At AACR Molecular Targets ConferenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH), reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). (Source: Pharma Industry News From Medical News Today)
Source: Pharma Industry News From Medical News Today - November 17, 2009 Category: Pharmaceuticals Tags: prostate / prostate Cancer Source Type: news

Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies Of Apoptone (HE3235) At AACR Molecular Targets And Cancer Therapeutics ConferenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH ), today reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - November 16, 2009 Category: Pharmaceuticals Source Type: news

Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expressionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The efficacy of current therapy for hormone-refractory prostate cancer is still unsatisfactory and new agents and therapeutic modalities are needed. The aims of the present work were to examine the in vitro activity and mechanisms of action of different antitumor drug combinations in hormone-resistant prostate cancer (HRPC) cell lines.The activity of docetaxel (Doc), cisplatin (Cis), oxaliplatin (Oxa), SN-38 and ST1481, singly or in combination, was assessed in different HRPC cell lines (PC3, parental DU145 and taxane-resistant DU145-R) by SRB test. Apoptosis was evaluated by TUNEL and ANN-V assays. Extrusion pump activity...
Source: The Prostate - September 28, 2009 Category: Urology & Nephrology Authors: Francesco Fabbri, Giovanni Brigliadori, Silvia Carloni, Paola Ulivi, Anna Tesei, Rosella Silvestrini, Dino Amadori, Wainer Zoli Source Type: journals

Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22rEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, total choline distributions in hormone sensitive CWR22 and hormone resistant CWR22r prostate cancer xenograft tumors in mice were measured before and at 4 h and 48 h after a single-bolus 17-allylamino, 17-demethoxygeldanamycin treatment at 100 mg/kg, using proton MR spectroscopy. Our results show that tumor total choline levels declined 4 h after the treatment for CWR22 (P = 0.001) and 48 h post treatment for CWR22r (P = 0.003). Metabolic changes, in particular of total choline intensity detected by proton magnetic resonance spectroscopic imaging (MRSI), are consistent with the observed immunohistochemistry ...
Source: Magnetic Resonance in Medicine - September 23, 2009 Category: Radiology Authors: H. Carl Le, Mihaela Lupu, Khushali Kotedia, Neal Rosen, David Solit, Jason A. Koutcher Source Type: journals

Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, total choline distributions in hormone sensitive CWR22 and hormone resistant CWR22r prostate cancer xenograft tumors in mice were measured before and at 4 h and 48 h after a single-bolus 17-allylamino, 17-demethoxygeldanamycin treatment at 100 mg/kg, using proton MR spectroscopy. Our results show that tumor total choline levels declined 4 h after the treatment for CWR22 (P = 0.001) and 48 h post treatment for CWR22r (P = 0.003). Metabolic changes, in particular of total choline intensity detected by proton magnetic resonance spectroscopic imaging (MRSI), are consistent with the observed immunohistochemistry ...
Source: Magnetic Resonance in Medicine - September 23, 2009 Category: Radiology Authors: Le HC, Lupu M, Kotedia K, Rosen N, Solit D, Koutcher JA Tags: Magn Reson Med Source Type: journals

A stochastic model for identifying differential gene pair co-expression patterns in prostate cancer progressionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: The SIG method reliably identifies cancer progression correlated gene pairs, and performs well both in gene pair ontology analysis and in pathway enrichment analysis. So, this method may provide an effective means of understanding the molecular mechanism of carcinogenesis by appropriately tracking down the process of cancer progression. (Source: BMC Genomics - Latest articles)
Source: BMC Genomics - Latest articles - July 28, 2009 Category: Genetics & Stem Cells Authors: Wen Juan MoXu Ping FuXiao Tian HanGuang Yuan YangJi Gang ZhangFeng Hua GuoYan HuangYu Min MaoYao LiYi Xie Source Type: journals

Annexin-A7 protects normal prostate cells and induces distinct patterns of RB-associated cytotoxicity in androgen-sensitive and -resistant prostate cancer cellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The tumor suppressor role of annexin-A7 (ANXA7) was previously demonstrated by cancer susceptibility in Anxa7(+/-)-mice and by ANXA7 loss in human cancers, especially in hormone-resistant prostate tumors. To gain mechanistic insights into ANXA7 tumor suppression, we undertook an in vitro study in which we compared wild-type (WT)-ANXA7 and dominant-negative (DN)-ANXA7 effects to a conventional tumor suppressor p53 in prostate cancer cells with different androgen sensitivity. Unlike p53 (which caused cell growth arrest and apoptosis to a noticeable extent in benign PrEC), WT-ANXA7 demonstrated profound cytotoxicityin androge...
Source: International Journal of Cancer - July 16, 2009 Category: Cancer & Oncology Authors: Yelizaveta Torosyan, Olga Simakova, Shanmugam Naga, Katerina Mezhevaya, Ximena Leighton, Juan Diaz, Wei Huang, Harvey Pollard, Meera Srivastava Source Type: journals

Antitumor Activity with CYP17 Blockade Indicates That Castration-Resistant Prostate Cancer Frequently Remains Hormone DrivenEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abiraterone acetate is a potent, selective, and orally bioavailable small molecule inhibitor of CYP17, an enzyme that catalyzes two key serial reactions (17 alpha hydroxylase and 17,20 lyase) in androgen and estrogen biosynthesis. Clinical trials have confirmed that specific inhibition of CYP17 is safe and results in clinically important antitumor activity in up to 70% of castrate patients with advanced prostate cancer resistant to currently available endocrine therapies. These clinical data indicate that castration-resistant prostate cancer frequently remains hormone dependent and has confirmed that this disease should no...
Source: Cancer Research - June 15, 2009 Category: Cancer & Oncology Authors: Attard, G., Reid, A. H.M., Olmos, D., de Bono, J. S. Tags: Clinical Research, Clinical Research: Response Markers and Mechanisms Reviews Source Type: journals

Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxelEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study we have addressed the mechanism of docetaxel-induced apoptosis of PC-3 cells and identified SphK1-dependent and -independent components. We have shown that SphK1 inhibition by docetaxel is a two-step process involving an initial loss of enzyme activity followed by a decrease in SphK1 gene expression. Using hormoneresistant PC-3 and DU145 PCa cells we have demonstrated that both pharmacological and siRNA-mediated SphK1 inhibition leads to a four-fold decrease in the docetaxel IC50 dose. This work points out to potential ways of increasing the effectiveness of chemotherapy for PCa by SphK1 inhibition. © 2009 U...
Source: International Journal of Cancer - June 10, 2009 Category: Cancer & Oncology Authors: Lysann Sauer, Joao Nunes, Vishal Salunkhe, Lenka Skalska, Takafumi Kohama, Olivier Cuvillier, Jonathan Waxman, Dmitry Pchejetski Source Type: journals

In vitro metabolism of the specific endothelin-A receptor antagonist ZD4054 and clinical drug interactions between ZD4054 and rifampicin or itraconazole in healthy male volunteers.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
ZD4054 is an oral specific endothelin-A receptor antagonist in development for the treatment of hormone-resistant prostate cancer. Both renal and metabolic processes contribute to its overall clearance. Two preclinical in vitro studies investigated the metabolism of ZD4054 using human liver microsomes, individual cytochrome P450 (CYP) isozymes, and flavin-containing monooxygenase isoforms. Two Phase I open-label crossover volunteer studies subsequently investigated in vivo drug interactions between ZD4054 and the CYP450 inducer rifampicin or CYP3A4 inhibitor itraconazole. The most abundant metabolite produced in in vit...
Source: Xenobiotica - May 31, 2009 Category: Research Authors: Swaisland HC, Oliver SD, Morris T, Jones HK, Bakhtyari A, Mackey A, McCormick AD, Slamon D, Hargreaves JA, Millar A, Taboada MT Tags: Xenobiotica Source Type: journals

PSA Decrease with Fulvestrant Acetate in a Hormone-Resistant Metastatic Prostate Cancer Patient: A Case ReportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Case Rep Oncol 2009;2:72-76 (DOI:10.1159/000214838) (Source: Karger Publishers)
Source: Karger Publishers - April 24, 2009 Category: Cancer & Oncology Source Type: journals

AR signature may improve hormone-resistant prostate cancer therapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A novel transcription-based activity signature is able to detect androgen receptor activity within individual prostate cancer specimens, say US scientists whose findings may help to improve care for patients with castration-resistant tumors. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - April 22, 2009 Category: Cancer & Oncology Source Type: news

AR signature may improve hormone-resistant prostate cancer therapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A novel transcription-based activity signature is able to detect androgen receptor activity within individual prostate cancer specimens, say US scientists whose findings may help to improve care for patients with castration-resistant tumors. (Source: MedWire News - Prostate Cancer)
Source: MedWire News - Prostate Cancer - April 22, 2009 Category: Cancer & Oncology Source Type: news

Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 TrialEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: The primary end point of time to progression was not achieved in this study, but an improvement was seen in overall survival in both active treatment arms. ZD4054 was well tolerated.Trial registration: Clinicaltrials.gov NCT00090363.Take Home Message: Specific endothelin-A receptor antagonist ZD4054 was associated with a promising improvement in overall survival compared with placebo and was generally well tolerated in patients with pain-free or mildly symptomatic metastatic hormone-resistant prostate cancer. Phase 3 trials are underway. (Source: European Urology)
Source: European Urology - April 21, 2009 Category: Urology & Nephrology Authors: Nicholas D. James, Armelle Caty, Michael Borre, Bernard A. Zonnenberg, Philippe Beuzeboc, Thomas Morris, De Phung, Nancy A. Dawson Tags: prostate Cancer Source Type: journals

Does chemotherapy have a role before hormone-resistant disease develops?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract  Recent studies have demonstrated a survival benefit for chemotherapy in metastatic hormone-resistant prostate cancer. In other malignancies such as breast or colorectal cancer, use of active chemotherapy regimens earlier in the course of the disease has resulted in improvements in disease-free and overall survival. This review discusses the status of chemotherapy in prostate cancer and addresses evidence regarding the use of chemotherapy in hormone-sensitive disease, alone and in combination with androgen deprivation therapy. Content Type Journal ArticleDOI 10.1007/s11934-009-0038-3Authors Jame...
Source: Current Urology Reports - April 21, 2009 Category: Urology & Nephrology Tags: Current Urology Reports Source Type: journals

Modern chemotherapy strategies for management of ‘Hormone Resistant Prostate Cancer’ (HRPC)—When should the urologist refer?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This article addresses many of these practical issues. (Source: British Journal of Medical and Surgical Urology)
Source: British Journal of Medical and Surgical Urology - April 18, 2009 Category: Urology & Nephrology Authors: Raj A. Persad, Amit Bahl Tags: Commissioned Review Source Type: journals

Pretreatment frequency of circulating IL-17+CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The aim of this study was to determine the prognostic implications of the pretreatment level of Th17 cells compared with regulatory T-cell status in prostate cancer patients receiving active whole cell immunotherapy. Ten-color flow cytometry was used to analyze IL-17-producing CD4+ T-cells in the peripheral blood of hormone-resistant non-bone metastatic prostate cancer patients prior to immunotherapy with an allogeneic whole-cell vaccine. Surface expression of the chemokine receptors CCR4 and CCR6 was used to further subdivide IL-17-producing cells into subsets with distinct homing properties. The frequency of circulating ...
Source: International Journal of Cancer - April 6, 2009 Category: Cancer & Oncology Authors: Evelyna Derhovanessian, Victoria Adams, Karin Hähnel, Andrea Groeger, Hardev Pandha, Stephen Ward, Graham Pawelec Source Type: journals

A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion-Resistant GrowthEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The androgen receptor (AR) plays a key role in progression to incurable androgen ablation–resistant prostate cancer (PCA). We have identified three novel AR splice variants lacking the ligand-binding domain (designated as AR3, AR4, and AR5) in hormone-insensitive PCA cells. AR3, one of the major splice variants expressed in human prostate tissues, is constitutively active, and its transcriptional activity is not regulated by androgens or antiandrogens. Immunohistochemistry analysis on tissue microarrays containing 429 human prostate tissue samples shows that AR3 is significantly up-regulated during PCA progression an...
Source: Cancer Research - March 17, 2009 Category: Cancer & Oncology Authors: Guo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., Kung, H.-J., Brodie, A. M.H., Edwards, J., Qiu, Y. Tags: Cell, Tumor, and Stem Cell Biology Source Type: journals

A 16-year clinical experience with intermittent androgen deprivation for prostate cancer: oncological resultsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions  Intermittent androgen deprivation is an acceptable treatment in different stages of PC. Duration of cycle decreased progressively during therapy. Age, Gleason score and PSA are factors predicting mortality. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00345-009-0393-1Authors Dominique Prapotnich, Université Paris Descartes Department of Urology, Institut Mutualiste Montsouris 42 Boulevard Jourdan 75014 Paris cedex FranceXavier Cathelineau, Université Paris Descartes Department of Urology, Institut Mutualiste Montsouris 42 Boulevard Jourdan 75014 Paris cedex FranceFran...
Source: World Journal of Urology - February 27, 2009 Category: Urology & Nephrology Tags: World Journal of Urology Source Type: journals

CTCs predict hormone-resistant prostate cancer survivalEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Circulating tumor cell numbers should be measured in men entering clinical trials for advanced metastatic prostate cancer, suggest researchers who say the marker should be used as a continuous variable. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - February 12, 2009 Category: Cancer & Oncology Source Type: news

CTCs predict hormone-resistant prostate cancer survivalEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Circulating tumor cell numbers should be measured in men entering clinical trials for advanced metastatic prostate cancer, suggest researchers who say the marker should be used as a continuous variable. (Source: MedWire News - Prostate Cancer)
Source: MedWire News - Prostate Cancer - February 12, 2009 Category: Cancer & Oncology Source Type: news

Circulating tumor cells as a potential efficacy end point in clinical trials of hormone-resistant prostate cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11934-009-0002-2Authors Samir S. Taneja Journal Current Urology ReportsOnline ISSN 1534-6285Print ISSN 1527-2737 Journal Volume Volume 10 Journal Issue Volume 10, Number 1 / January, 2009 (Source: Current Urology Reports)
Source: Current Urology Reports - January 11, 2009 Category: Urology & Nephrology Tags: Current Urology Reports Source Type: journals

Phase II Study Shows That ZD4054 Could Improve Survival For Hormone Resistant Prostate Cancer (HRPC) Patients With Bone MetastasesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A novel compound in development by AstraZeneca as an oral tablet for hormone resistant prostate cancer (HRPC), ZD4054, could improve overall survival (OS) in men with metastatic HRPC, according to Phase II data published today in European Urology.[1] Men with advanced prostate cancer may receive initially effective treatment with hormonal therapies to which the majority of prostate cancers can later become resistant. (Source: Cancer / Oncology News From Medical News Today)
Source: Cancer / Oncology News From Medical News Today - December 3, 2008 Category: Cancer & Oncology Tags: prostate / prostate Cancer Source Type: news

Molecular markers in prostate cancer. Part II: potential roles in management.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Predicting treatment responses in advanced prostate cancer (PCa) currently centres on prostate-specific antigen (PSA) kinetics and on being able to visualize measurable changes in imaging modalities. New molecular markers have emerged as potential diagnostic and prognostic indicators; these were summarized in Part I of this review in the Asian Journal of Andrology. A number of molecular markers are now being used to enhance PCa imaging and staging. However, management options for advanced and hormone-resistant PCa (HRPC) are limited and additional therapeutic options are needed. Molecular markers have been proposed as ...
Source: Asian Journal of Andrology - December 1, 2008 Category: Urology & Nephrology Authors: Agrawal S, Patil KP, Dunsmuir WD Tags: Asian J Androl Source Type: journals

Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: The primary end point of time to progression was not achieved in this study, but an improvement was seen in overall survival in both active treatment arms. ZD4054 was well tolerated. TRIAL REGISTRATION: Clinicaltrials.gov NCT00090363. PMID: 19042080 [PubMed - as supplied by publisher] (Source: European Urology)
Source: European Urology - November 28, 2008 Category: Urology & Nephrology Authors: James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA Tags: Eur Urol Source Type: journals

Marillion Acquires Exclusive Worldwide Rights To 177Lu-AMBA , A First In Class Targeted Radiotherapeutic For Advanced Prostate CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
MALVERN, Pa. & PRINCETON, N.J. -- Marillion Pharmaceuticals Inc. and Bracco Imaging S.p.A., one of the world's leading companies in the diagnostic imaging business and part of the Bracco Group, announced today that the two companies have entered into a license agreement granting Marillion exclusive worldwide rights to complete clinical development and to commercialize Bracco's (177)Lu-AMBA for the treatment of hormone-resistant prostate and advanced (metastatic) breast cancers. According to the World Health Organization (WHO), prostate and breast cancers affect more than 4 million patients via new diagnoses each year. Pros...
Source: Cancercompass News: Prostate Cancer - November 13, 2008 Category: Cancer & Oncology Source Type: news

Marillion Pharmaceuticals and Bracco Imaging S.p.A. Announce License Agreement to Develop and Commercialize Novel Cancer Treatment : Marillion acquires exclusive worldwide rights to 177Lu-AMBA, a first in class targeted radiotherapeutic for advanced prostate and breast cancers discovered and developed by Bracco Imaging S.p.A.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Marillion Pharmaceuticals Inc. and Bracco Imaging S.p.A., one of the world’s leading companies in the diagnostic imaging business and part of the Bracco Group, announced today that the two companies have entered into a license agreement granting Marillion exclusive worldwide rights to complete clinical development and to commercialize Bracco’s 177Lu-AMBA for the treatment of hormone-resistant prostate and advanced (metastatic) breast cancers. (PRWeb Nov 11, 2008) Read the full story at http://www.prweb.com/releases/bracco_imaging/bracco_group/prweb1601944.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 12, 2008 Category: Pharmaceuticals Source Type: news

Prostate cancer Multidisciplinary approach: a key to success.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Diagnosis and treatment of prostate cancer has improved in the last few years, in part due to a multidisciplinary approach between urologists, oncologists, radiotherapists, radiologists, pathologists, basic and translational researchers for a successful management. The TAX 327 study is the paradigm of a smooth communication between expert physicians that led to the approval of docetaxel in metastatic hormone-resistant prostate cancer (HRPC). Survival benefit with docetaxel in HRPC was confirmed in an updated survival analysis reported this year. A nomogram to predict survival in metastatic HRPC treated with chemotherap...
Source: Critical Reviews in Oncology Hematology - August 22, 2008 Category: Cancer & Oncology Authors: Montagut C, Albanell J, Bellmunt J Tags: Crit Rev Oncol Hematol Source Type: journals

Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell lineEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: The zoledronic acid-docetaxel combination produced a highly significant synergistic effect on the LNCaP cell line grown in normal or hormone-deprived medium, the principal molecular mechanisms involved being apoptosis and decreased pMEK and Mcl-1 expression. This experimentally derived schedule would seem to prevent the selection and amplification of hormone-resistant cell clones and could thus be potentially used alongside standard androgen deprivation therapy in the management of hormone-sensitive prostate carcinoma. (Source: Journal of Translational Medicine)
Source: Journal of Translational Medicine - August 8, 2008 Category: Research Authors: Francesco Fabbri, Giovanni Brigliadori, Silvia Carloni, Paola Ulivi, Ivan Vannini, Anna Tesei, Rosella Silvestrini, Dino Amadori and Wainer Zoli Source Type: journals

Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme In Prostate Cancer ModelsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, announced the presentation of positive pre-clinical animal efficacy data for its pegylated-rHuPH20 enzyme (PEGPH20) at the American Association for Cancer Research (AACR) Translational Cancer Medicine meeting in Monterey, CA. The study showed that treatment of hormone resistant human prostate cancer in tumor bearing mouse models with intravenous PEGPH20 in combination with the chemotherapeutic drugs, docetaxel (Taxotere(R)) or liposomal doxorubicin (Doxil(R)) resulted in a substantial increas...
Source: Cancercompass News: Prostate Cancer - August 1, 2008 Category: Cancer & Oncology Source Type: news

Infinity and MedImmune Announce Approval for Generic Name for Novel Hsp90 InhibitorEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CAMBRIDGE, Mass. and GAITHERSBURG, Md., Feb. 4, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune today announced that the United States Adopted Names (USAN) Council, in consultation with the World Health Organization (WHO) International Nonproprietary Names Expert Committee, has approved the use of the nonproprietary or generic name "retaspimycin" for the companies' lead heat shock protein 90 (Hsp90) inhibitor, IPI-504. Retaspimycin hydrochloride is currently being evaluated in clinical trials for the potential treatment of a variety of solid tumor cancers, including gastroi...
Source: Medical News (via PRIMEZONE) - February 4, 2008 Category: Pharmaceuticals Source Type: news

A docetaxel plus prednisone regimen "remains the preferred treatment option" in most men with metastatic, hormone-resistant prostate cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Inpharma)
Source: Inpharma - January 29, 2008 Category: Drugs & Pharmacology Tags: Research article Source Type: journals

Updated survival data from TAX 327 study shows docetaxel plus prednisone superior to mitoxantrone plus prednisone for advanced prostate cancer?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
According to an updated analysis of the TAX 327 study, treatment of advanced prostate cancer with 3-weekly docetaxel in addition to prednisone resulted in statistically significantly longer survival times compared to treatment with mitoxantrone in combination with prednisone. The TAX 327 study had compared docetaxel administered every 3 weeks (D3), weekly docetaxel (D1), and mitoxantrone (M), each with prednisone (P), in 1,006 men with metastatic hormone-resistant prostate cancer (HRPC). The initial analysis at Aug 2003 when 557 deaths had already occurred, had shown statistically significant better survival and response ...
Source: NeLM news - Cancer - January 29, 2008 Category: Cancer & Oncology Tags: 8.1.5 Other antineoplastic drugs, Cancer: prostate Source Type: organizations

Docetaxel Every Three Weeks Best for Certain Metastatic Prostate CancersEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The survival of patients with hormone-resistant prostate cancer is significantly longer after treatment with docetaxel every 3 weeks with prednisone (D3P) compared with other regimens, according to the follow-up of a major study. Reuters Health Information (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - January 28, 2008 Category: Drugs & Pharmacology Tags: Hematology-Oncology Source Type: info

A docetaxel plus prednisone regimen "remains the preferred treatment option" in most men with metastatic, hormone-resistant prostate cancer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Page: 12 (Source: Inpharma Weekly)
Source: Inpharma Weekly - January 26, 2008 Category: Drugs & Pharmacology Tags: HTML Source Type: journals

Down-regulation of androgen-receptor and PSA by phytochemicals.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study describes the effects of three of these compounds (oridonin, isoliquiritigenin and wogonin) on cell proliferation, cell apoptosis, cell cycle parameters, AR and PSA protein expression. In each case, these compounds have independent activities which may partly contribute to the biological activity of PC-SPES. PMID: 18202763 [PubMed - in process] (Source: International Journal of Oncology)
Source: International Journal of Oncology - January 20, 2008 Category: Cancer & Oncology Authors: Chen S, Gao J, Halicka HD, Traganos F, Darzynkiewicz Z Tags: Int J Oncol Source Type: journals

Jefferson Scientists Find Protein Potential Drug Target For Treatment-resistant Prostate CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PHILADELPHIA -- Scientists at Jefferson Kimmel Cancer Center in Philadelphia have found that a signaling protein that is key to prostate cancer cell growth is turned on in nearly all recurrent prostate cancers that are resistant to hormone therapy. If the findings hold up, the protein, called Stat5, may be a specific drug target against an extremely difficult-to-treat cancer. In addition, the researchers, led by Marja Nevalainen, M.D., Ph.D., associate professor of Cancer Biology at Jefferson Medical College of Thomas Jefferson University, also showed that the convergence of two biological pathways could be responsible for...
Source: Cancercompass News: Prostate Cancer - January 17, 2008 Category: Cancer & Oncology Source Type: news

[Genitourinary Cancer] Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 StudyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion The present analysis confirms that survival of men with metastatic HRPC is significantly longer after treatment with D3P than with MP. Consistent results are observed across subgroups of patients. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - January 8, 2008 Category: Cancer & Oncology Authors: Berthold, Pond, Soban, de Wit, Eisenberger, Tannock Tags: Genitourinary Cancer Source Type: journals

[Chemotherapy for prostate cancer.]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Chemotherapy treatment for patients with prostate cancer has advanced considerably during the past decade. The first demonstration of the efficacy of palliative chemotherapy in patients with hormone-resistant prostate cancer was followed by FDA approval of mitoxantrone in this setting and by studies showing the usefulness of several different drugs in these patients. Docetaxel became the standard treatment for them. The development of new cytotoxic molecules and targeted therapies as well as the evaluation of the efficacy of docetaxel in earlier stages of prostate cancer, with many ongoing studies, are the current line...
Source: Presse Medicale - December 19, 2007 Category: Journals (General) Authors: Medioni J, Dionysopoulos D, Banu E, Scotté F, Beuzeboc P, Oudard S Tags: Presse Med Source Type: journals

The androgen receptor as putative therapeutic target in hormone-refractory prostate cancer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The androgen receptor (AR) plays a central role in the initiation and growth of prostate cancer. Androgen deprivation therapy (ADT) has been a gold standard for advanced prostate cancer for decades. Unfortunately, suppressive effects of ADT do not last long and hormone-refractory prostate cancer develops within several years. In spite of extensive research on mechanisms of hormone-independent growth of prostate cancer, there are few effective treatment options for recurrent tumors and most patients die from the disease in a short period of time. Accumulating evidence suggests that the AR signaling system remains intact...
Source: Recent Patents on Anti-Cancer Drug Discovery - November 1, 2007 Category: Cancer & Oncology Authors: Kageyama Y, Hyochi N, Kihara K, Sugiyama H Tags: Recent Patents Anticancer Drug Discov Source Type: journals

Transcriptional Regulation of Human Protease-Activated Receptor 1: A Role for the Early Growth Response-1 Protein in Prostate CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Transcriptional regulation plays a central role in the molecular pathways underlying preferential cancer growth and metastasis. In the present study, we investigated the regulation of human protease-activated receptor 1 (hPar1) gene overexpression in the malignant androgen hormone-resistant phase. We found increased hPar1 RNA chain elongation and no change in message stability in cells with high levels of PAR1 expression, indicating that increased transcription is largely responsible for the overexpression of hPar1 in prostate tumor progression. Enforced expression of early growth response-1 (Egr-1) plasmid markedly enhanc...
Source: Cancer Research - October 17, 2007 Category: Cancer & Oncology Authors: Salah, Z., Maoz, M., Pizov, G., Bar-Shavit, R. Tags: Cell, Tumor, and Stem Cell Biology Source Type: journals

A specific endothelin A receptor antagonist, ZD 4054, may increase overall survival among patients with hormone-resistant prostate cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Inpharma)
Source: Inpharma - October 8, 2007 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

A specific endothelin A receptor antagonist, ZD 4054, * may increase overall survival among patients with hormone-resistant prostate cancer,.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Page: 14 (Source: Inpharma Weekly)
Source: Inpharma Weekly - October 6, 2007 Category: Drugs & Pharmacology Tags: HTML Source Type: journals

Investigational therapy for hormone-resistant PCa shows survival advantageEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The investigational compound ZD4054, an endothelin-A receptor antagonist, appears to positively impact overall survival in patients with hormone-resistant prostate cancer, according to the results of a randomized, double-blind, placebo-controlled, phase II study presented at the European Congress of Clinical Oncology in Barcelona. (Source: UrologyTimes - Prostate Cancer)
Source: UrologyTimes - Prostate Cancer - October 2, 2007 Category: Urology & Nephrology Source Type: journals

Efficacy of Low-dose Ketoconazole in Hormone Refractory Prostate Cancer Patients at the National Cancer Centre and The Cancer Institute, Singapore.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Low-dose ketoconazole bridges the gap in the continuum of treatment for patients who have failed ADT and in whom cytotoxic chemotherapy would have a significant impact on the quality of life. Its good toxicity profile, low cost and ease of administration makes it a viable option for this group of patients. PMID: 17987231 [PubMed - in process] (Source: Ann Acad Med Singapo...)
Source: Ann Acad Med Singapo... - October 1, 2007 Category: Journals (General) Authors: Ngo LS, Yeo A, Wong AS, Tay MH Tags: Ann Acad Med Singapore Source Type: journals

Announcing Wide-Ranging ZD4054 Phase III Development Program For Prostate Cancer TreatmentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
New Phase II data presented suggest that ZD4054, a novel compound in development for the treatment of men with Hormone Resistant Prostate Cancer (HRPC), could offer a promising improvement in overall survival in men with metastatic HRPC who were asymptomatic or mildly symptomatic for pain. [click link for full article] (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 27, 2007 Category: Consumer Health News Source Type: news

New AstraZeneca compound shows promoise for hormone resistant prostate cancer patients with bone metastasesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
New Phase II data suggests that ZD4054, a novel compound in development for the treatment of men with Hormone Resistant Prostate Cancer (HRPC), could offer a promising improvement in overall survival in men with metastatic HRPC who were asymptomatic or mildly symptomatic for pain. (Source: News-Medical News Feed)
Source: News-Medical News Feed - September 26, 2007 Category: Consumer Health News Source Type: news

Survival data presented from phase II study of hormone-resistant prostate cancer patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The results from the randomized, double -blind, placebo -controlled, Phase II EPOC (Endothelin A Proof Of Concept) Study of ZD4054 - a specific endothelin A (ETA) receptor antagonist – were delivered at the 14th European Congress of Clinical Oncology (ECCO, 23-27 September, Barcelona). (Source: News-Medical News Feed)
Source: News-Medical News Feed - September 26, 2007 Category: Consumer Health News Source Type: news

ECCO: Investigational Drug Shows Survival Edge in Advanced Prostate CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
BARCELONA, Spain -- An investigational drug that blocks key cancer growth messages appears to give patients with metastatic hormone resistant prostate cancer an extra six months' survival. (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 25, 2007 Category: American Health Source Type: info